Zilast 50 Tablet contains Cilostazol 50 mg, a phosphodiesterase III inhibitor indicated primarily for the treatment of intermittent claudication due to peripheral arterial disease. Cilostazol works by inhibiting platelet aggregation and inducing vasodilation, thereby improving blood flow to the limbs and reducing symptoms such as pain and cramping during walking. This medication is typically prescribed to patients experiencing impaired circulation caused by atherosclerosis or other vascular conditions. Zilast 50 should be used under medical supervision, with dosage adjustments based on clinical response and tolerability. Common side effects may include headache, diarrhea, dizziness, and palpitations, while serious adverse effects such as bleeding or arrhythmias require immediate attention. It is contraindicated in patients with heart failure, active bleeding, or hypersensitivity to Cilostazol or its components. Caution is advised when administered concomitantly with anticoagulants, antiplatelet agents, or drugs metabolized by CYP3A4 and CYP2C19 enzymes. Regular monitoring of cardiovascular status and hematologic parameters is recommended during therapy. Zilast 50 Tablet offers a therapeutic option to enhance walking distance and quality of life in patients with peripheral arterial disease by improving microcirculation and reducing ischemic symptoms.